<SEC-DOCUMENT>0001213900-23-020762.txt : 20230317
<SEC-HEADER>0001213900-23-020762.hdr.sgml : 20230317
<ACCEPTANCE-DATETIME>20230317092643
ACCESSION NUMBER:		0001213900-23-020762
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230317
FILED AS OF DATE:		20230317
DATE AS OF CHANGE:		20230317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		23740854

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea175394-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES AND
EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Tiziana Life
Sciences LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>107 Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>EC2V 6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F
&#9746;&nbsp;Form&nbsp;40-F &#9744; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate by
check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7):&nbsp;</FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 17, 2023, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;)
issued a press release, announcing the Company was highlighted in a FORBES article highlighting foralumab, the Company&rsquo;s unique intranasal
monoclonal antibody, which is currently in clinical development to treat multiple sclerosis and a range of other neurodegenerative diseases.
Foralumab is the world&rsquo;s only fully human, anti-CD3 mAb in clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: March 17, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea175394ex99-1_tiziana.htm">News Service Announcement, dated March 17, 2023</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea175394ex99-1_tiziana.htm
<DESCRIPTION>NEWS SERVICE ANNOUNCEMENT, DATED MARCH 17, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences Highlighted in Forbes
Article</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Article entitled &ldquo;New T Cell Antibody Treatment
Improves Outcomes For Covid Patients&rdquo; reviews the company&rsquo;s first in class foralumab, a unique Intranasal monoclonal antibody designed
to treat multiple sclerosis and a range of other neurodegenerative diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK,&nbsp;March 17, 2023 -- Tiziana Life
Sciences Ltd.&nbsp;(Nasdaq: TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough
immunomodulation therapies via novel routes of drug delivery, today announced that the Company was highlighted in a FORBES article highlighting
foralumab, the Company&rsquo;s unique intranasal monoclonal antibody, which is currently in clinical development to treat multiple sclerosis
and a range of other neurodegenerative diseases. Foralumab is the world&rsquo;s only fully human, anti-CD3 mAb in clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forbes contributing author, <B>William A. Haseltine</B>,
highlighted foralumab in his article entitled <I>&ldquo;New T Cell Antibody Treatment Improves Outcomes for Covid Patients&rdquo;</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Noted in the article was:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&ldquo;Foralumab induces many factors that
impact improved tissue remodeling, induction of immune cells, and restriction of effector function, improving disease outcomes while fighting
the virus to full strength. These benefits are not limited to Covid-19 patients, as similar results were observed in patients with multiple
sclerosis.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&ldquo;The anti-CD3 monoclonal treatment effectively
modulates the T cell inflammatory response by up or downregulating specific gene and protein expressions, resulting in less severe disease.
This novel avenue should be further explored, as more drugs with similar mechanisms could prevent the deaths of thousands.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>To access <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
full Forbes article, please visit the following link:</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.forbes.com/sites/williamhaseltine/2023/03/16/new-t-cell-antibody-treatment-improves-outcomes-for-covid-patients/?sh=4cfb63eb670f</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Foralumab</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Activated T cells play an important role in the
inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation
by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients
with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start
in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory
human diseases. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About&nbsp;Tiziana Life Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tiziana Life Sciences&nbsp;is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana&rsquo;s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab,
the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s
technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad
pipeline applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B><BR>
Irina Koffler<BR>
LifeSci Advisors, LLC<BR>
646.970.4681<BR>
ikoffler@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# 28# 2(  A$! Q$!_\0
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MYQO_ ,)O?ML;:MD03C@?,M?3G6HH;6WMRQA@BC+?>*(%S]<4 2UY+^T0CO\
M#F JI(74(RQ Z#8XY_,5ZU3)(HYHS'+&LB'JK#(/X4 >3?L\H\?P[N79& :^
MD*Y_B^51Q^->(?$+QOXC\4ZU<6^K2R0V]O,RQV2@JD>#CD=S[FOLB**.&,1Q
M1K&@Z*HP!^%12V%G,Y>6T@D<]6>,$T ?&W@OQC:>#[@WG_".6FHWP.8Y[EV_
M=C_97& ??K7H8_:3UC//AZR_[_/7T'_9>G_\^%K_ -^5_P */[+T_P#Y\+7_
M +\K_A0!\_?\-*:K_P!"Y:?]_P!O\*]'^%OQ+N?B"NHBYTI;,VA3#QN65]V>
M.1U&/UKNO[+T_P#Y\+7_ +\K_A4\-O!;*5@ACB4G)"*%!_*@#Y1OX96_:)=%
MC8L=;! QSC<#7N_Q8\$W'CCPA]CL747UM*)X%<X5R 05)[9!KMOLMN9_/\B+
MSO\ GIL&[\^M2T ?)_ASQWXT^%*/H]UI/^BB0N;>[B9<,>NUQV/XBND_X:4U
M7_H7+3_O^W^%?1,L,4R[98TD7T=015?^R]/_ .?"U_[\K_A0!\_?\-*:K_T+
MEI_W_;_"N3\5^./%?Q8FM--@TC]S%)OCM[2-FRQ&,LQ_^L.:^K?[+T__ )\+
M7_ORO^%3Q00P+MABCC'HB@?RH X3PCX4N?"/PDFTFZ(:\-K/+,J<@.RD[1ZX
MX%>,?L]PR'XCR.(VVI9R;CC[N2.M?4U116MO S-#!%&S?>*( 3]<4 2T444
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MO+^[N56W4J)YWD .[MN)Q78?$N+/A-[A9)HIK9Q+$\,SQE6 (SE2,]>AHHH
CY7X1Z?;:W#>ZWJR-?ZD<0?:+J1I2(^NT!B0!D#I1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
